PDF(Sci-hub)
Abstract：
Immunotherapy has been proven effective in several tumours, hence diverse immune checkpoint inhibitors are currently licensed for the treatment of melanoma, kidney cancer, lung cancer and most recently, tumours with microsatellite instability. There is much enthusiasm for investigating this approach in gynaecological cancers and the possibility that immunotherapy might become part of the therapeutic landscape for gynaecological malignancies. Cervical cancer is the fourth most frequent cancer in women worldwide and represents 7.9% of all female cancers with a higher burden of the disease and mortality in low- and middle-income countries. Cervical cancer is largely a preventable disease, since the introduction of screening tests, the recognition of the human papillomavirus (HPV) as an etiological agent, and the subsequent development of primary prophylaxis against high risk HPV subtypes. Treatment for relapsed/advanced disease has improved over the last 5 years, since the introduction of antiangiogenic therapy. However, despite advances, the median overall survival for advanced cervical cancer is 16.8 months and the 5-year overall survival for all stages is 68%. There is a need to improve outcomes and immunotherapy could offer this possibility. Clinical trials aim to understand the best timing for immunotherapy, either in the adjuvant setting or recurrent disease and whether immunotherapy, alone or in combination with other agents, improves outcomes.
摘要：
免疫疗法已被证明对几种肿瘤有效，因此，目前有多种免疫检查点抑制剂被许可用于治疗黑色素瘤，肾癌,肺癌和最近的，具有微卫星不稳定性的肿瘤。在妇科癌症中研究这种方法的热情很大，并且免疫疗法可能成为妇科恶性肿瘤治疗领域的一部分。宫颈癌是全球女性中第四常见的癌症，占所有女性癌症的7.9%，在低收入和中等收入国家，宫颈癌负担和死亡率更高。宫颈癌在很大程度上是一种可预防的疾病，自从引入筛查测试以来，将人乳头瘤病毒（HPV）识别为病原体，以及随后针对高危HPV亚型的初级预防的发展。复发/晚期疾病的治疗在过去5年中有所改善，自从引入抗血管生成治疗以来。然而,尽管取得了进展，晚期宫颈癌的中位总生存期为16.8个月,所有分期的5年总生存期为68%.需要改善结果，免疫疗法可以提供这种可能性。临床试验旨在了解免疫治疗的最佳时机。无论是在辅助治疗还是复发性疾病，无论是免疫疗法，单独或与其他药物联合使用，改善结果。
